For more information, please visit the Company's website atwww.cardima.com.

Forward-Looking Statements

Except for the historical information contained herein, the mattersdiscussed in this press release are forward-looking statements that involverisks and uncertainties that could cause actual results to differmaterially from those expressed in or implied by such forward-lookingstatements, including but not limited to building a robust body of data toassist in the establishment of linear ablation systems as a safe andeffective tool for the treatment of AF. Potential risks and uncertaintiesinclude, but are not limited to: the uncertainties associated with theprospects for FDA approval of any new devices; the prospect for any futureclinical trials or regulatory activities; the risk that the Company willnot be able to raise additional capital in the immediate term as needed tocontinue operations and the risk that we will be unable to secure FDAapproval for the EP ablation applications in the USA and CE mark for theSurgical Ablation probe series with Sheath. Additional risks anduncertainties are set forth in the Company's Annual Report on Form 10-KSBfor the year ended December 31, 2007, the Company's Quarterly Report onForm 10-QSB and in the Company's other filings with the Securities andExchange Commission. The Company undertakes no obligation to publiclyrelease the result of any revisions to these forward-looking statementsthat may be made to reflect events or circumstances after the date hereof,or to reflect the occurrence of unanticipated events or changes in theCompany's plans or expectations.